In order to obtain additional information on whether Cyr61 can be applied as a detection marker for CTC and DTC, we investigated the typical microenvironmental conditions that are common under ischemia in breast tumors, and determined the changes of the Cyr61 levels in response to these conditions. The gene discussed is CCN1; the disease is breast neoplasm.